

Special Issue

Cell Therapy for Cardiac Disease

Message from the Guest Editors

Dear colleagues,

The treatment of cardiac and vascular outcomes is becoming an intriguing global target due to the high morbidity and mortality related to these pathological conditions. In addition to drug treatments that have produced significant results in preventing and treating cardiovascular diseases, the personalized medicine approach seems to be a great opportunity for clinical intervention. In this scenario, human induced pluripotent stem cells (hiPSC) represent a possible tool to be used in a two-way approach: first, in regenerative medicine, particularly those conditions related to the loss of heart function, and second, as a cellular model able to be used instead of animals.

This Special Issue aims to present discoveries in the differentiation procedures, function, and physiological and metabolic characterization of hiPSC-derived cells, focusing on their use in treating cardiovascular diseases or drug screening. Original research papers, critical up-to-date articles, and reviews on the potential use of hiPSC in cardiac and vascular pathologies are welcome.

Guest Editors

Dr. Daniela Malan

Institute of Physiology I, University of Bonn, Nußallee 11, 53115 Bonn, Germany

Dr. Giulia Querio

Department of Life Sciences and Systems Biology, University of Turin, Via Accademia Albertina 13, 10123 Turin, Italy

Deadline for manuscript submissions

closed (15 May 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/165917

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)